Emergent buys ABEC bioreactor to transfer raxibacumab to Baltimore facility

By Gareth Macdonald 

Bioterrorism countermeasure manufacturer Emergent Biosciences has bought a 4,000L bioreactor developed by ABEC.

Read the article.